Development of more erratic heart rate patterns is associated with mortality post-myocardial infarction

J Electrocardiol. 2008 Mar-Apr;41(2):110-5. doi: 10.1016/j.jelectrocard.2007.11.005.

Abstract

Cardiac patients often have sinus arrhythmia of nonrespiratory origin (erratic sinus rhythm [ESR]). ESR was quantified using hourly Poincaré and power spectral heart rate variability plots from normal-to-normal interbeat intervals and hourly values of the short-term fractal scaling exponent and correlations of normal-to-normal intervals in n = 60 nonsurvivors and n = 66 randomly selected survivors in the Cardiac Arrhythmia Suppression Trial. Hours were coded (ABN) as normal (0), borderline (0.5), or ESR (1). t Tests compared ABN for n = 2413 paired hours at baseline and on therapy. ABN was higher in nonsurvivors (0.38 +/- 0.44 vs 0.28 +/- 0.40, baseline, and 0.51 +/- 0.45 vs 0.34 +/- 0.43, on therapy, P < .001). Increased ABN with treatment were greater in nonsurvivors. Normal hours at baseline (relative risk = 0.77; 095% confidence interval, 0.62-0.96, P = .018) and on treatment (relative risk = 0.47; 95% confidence interval, 0.39-0.58) were significantly associated with decreased mortality compared with ESR. Quantification of ESR may identify more vulnerable patients or help monitor the effects of pharmacologic treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use*
  • Arrhythmias, Cardiac / diagnosis
  • Arrhythmias, Cardiac / drug therapy*
  • Arrhythmias, Cardiac / mortality*
  • Comorbidity
  • Electrocardiography, Ambulatory / methods
  • Electrocardiography, Ambulatory / statistics & numerical data*
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Missouri / epidemiology
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / prevention & control*
  • Prognosis
  • Risk Assessment / methods*
  • Risk Factors
  • Survival Analysis
  • Survival Rate

Substances

  • Anti-Arrhythmia Agents